Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 93.14M | 93.16M | 90.17M | 90.12M | 88.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 93.14M | 93.16M | 90.17M | 90.12M | 88.26M |
| Cost of Revenue | 29.99M | 37.99M | 35.24M | 33.77M | 32.72M |
| Gross Profit | 63.15M | 55.17M | 54.93M | 56.35M | 55.54M |
| SG&A Expenses | 76.94M | 79.13M | 76.49M | 77.42M | 82.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.03M | 228.26M | 222.83M | 225.35M | 233.71M |
| Operating Income | -135.90M | -135.10M | -132.66M | -135.23M | -145.45M |
| Income Before Tax | -168.31M | -177.16M | -176.01M | -276.26M | -290.69M |
| Income Tax Expenses | -9.00K | -79.00K | -172.00K | -200.00K | 2.97M |
| Earnings from Continuing Operations | -168.30 | -177.08 | -175.84 | -276.06 | -293.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -168.30M | -177.08M | -175.84M | -276.06M | -293.67M |
| EBIT | -135.90M | -135.10M | -132.66M | -135.23M | -145.45M |
| EBITDA | -130.19M | -128.69M | -125.54M | -127.41M | -136.11M |
| EPS Basic | -0.84 | -0.90 | -0.92 | -1.46 | -1.55 |
| Normalized Basic EPS | -0.45 | -0.46 | -0.45 | -0.47 | -0.51 |
| EPS Diluted | -0.84 | -0.90 | -0.92 | -1.46 | -1.56 |
| Normalized Diluted EPS | -0.45 | -0.46 | -0.45 | -0.47 | -0.51 |
| Average Basic Shares Outstanding | 803.86M | 785.02M | 765.85M | 759.98M | 757.17M |
| Average Diluted Shares Outstanding | 803.86M | 785.02M | 765.85M | 759.98M | 757.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
